CWP 232291

Drug Profile

CWP 232291

Alternative Names: CWP 291; CWP232291

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JW Pharmaceutical
  • Class Antineoplastics; Peptidomimetics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Gastric cancer; Multiple myeloma
  • Preclinical Solid tumours

Most Recent Events

  • 23 Mar 2018 Phase-I clinical trials in Gastric cancer in South Korea (Intraperitoneal) before March 2018 (JW Pharmaceutical pipeline, March 2018)
  • 02 Jun 2017 Preclinical trials in Gastrointestinal cancer in South Korea (Intraperitoneal) before June 2017
  • 02 Jun 2017 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top